Life Sciences, Current

MGB Biopharma

MGB Biopharma is a biopharmaceutical company focussed on the development of a new class of antibiotic.

Its lead candidate, MGB-BP-3, is a potent bactericidal antibiotic with a completely novel mode of action for the treatment of Clostridium difficile Infection (CDI). CDI is a serious and often life-threatening infection of the large intestine and is the most frequent cause of diarrhoea in hospitals and care homes. In the US alone, there are almost half a million cases every year associated with around 30,000 deaths; three people die of uncontrolled CDI every hour.

Year of investment



Sarah Hardy

Seeking investment?

Our team is always actively seeking new investment opportunities. They review circa 200 business plans each year.

Become a member

Our members are genuinely motivated to give something back and build great businesses in Scotland, as well as making a financial return.

We use cookies to give you the best experience. Cookie Policy

Preloader image